中山全市研发经费投入连续三年超百亿，康方生物7个新药已上市

Group 1 - The core achievement of Zhongshan during the "14th Five-Year Plan" period includes a continuous increase in GDP, surpassing 3500 billion and 4000 billion yuan, with an expected breakthrough of 4200 billion yuan by 2025 [2] - The total number of business entities in Zhongshan reached 740,000, marking a 60% growth over five years [2] - The number of provincial industrial parks increased from 3 to 11, and the total scale of the ten major industrial clusters exceeded 7000 billion yuan, with industrial investment expected to double by 2024 compared to 2021 [2] Group 2 - Zhongshan emphasizes innovation as the primary driving force for development, focusing on strengthening innovation supply, activating enterprise innovation, and improving financial support ecosystems [3] - The city invested nearly 5 billion yuan over five years to build high-level innovation platforms, collaborating with institutions like the Chinese Academy of Sciences and various universities [3] - R&D expenditure in Zhongshan has exceeded 10 billion yuan for three consecutive years, with a growth rate of over 20% for the last two years [3] - The biopharmaceutical industry in Zhongshan has established an ecosystem with a production value of 18 billion yuan, gathering over 650 related enterprises [3] - Special policies have been introduced to support innovative drug research and development, with funding support of up to 40% and a maximum of 65 million yuan per product [3] - R&D investment in the biopharmaceutical sector is expected to double from 2021 to 2024, with an average growth rate of over 30% in the last two years [3]